BidaskClub cut shares of Akcea Therapeutics (NASDAQ:AKCA) from a buy rating to a hold rating in a report published on Saturday morning.

Other equities analysts have also recently issued research reports about the stock. Stifel Nicolaus reissued a buy rating and issued a $20.00 price target (up previously from $19.00) on shares of Akcea Therapeutics in a research note on Tuesday, November 7th. Cowen restated a buy rating on shares of Akcea Therapeutics in a report on Tuesday, October 31st. Finally, Zacks Investment Research upgraded shares of Akcea Therapeutics from a sell rating to a hold rating in a report on Thursday, November 9th. Two analysts have rated the stock with a hold rating and four have issued a buy rating to the company’s stock. The company currently has an average rating of Buy and an average target price of $24.00.

Akcea Therapeutics (NASDAQ:AKCA) opened at $17.36 on Friday. Akcea Therapeutics has a 12 month low of $8.10 and a 12 month high of $31.23. The company has a market cap of $1,230.00 and a P/E ratio of -4.41.

Several institutional investors and hedge funds have recently made changes to their positions in the company. Granahan Investment Management Inc. MA bought a new stake in shares of Akcea Therapeutics in the 3rd quarter worth approximately $8,528,000. OxFORD Asset Management LLP bought a new stake in Akcea Therapeutics during the 3rd quarter valued at $6,872,000. Candriam Luxembourg S.C.A. bought a new stake in Akcea Therapeutics during the 3rd quarter valued at $5,314,000. Schwab Charles Investment Management Inc. bought a new stake in Akcea Therapeutics during the 3rd quarter valued at $1,654,000. Finally, Bank of New York Mellon Corp bought a new stake in Akcea Therapeutics during the 3rd quarter valued at $1,413,000. Hedge funds and other institutional investors own 26.04% of the company’s stock.

COPYRIGHT VIOLATION WARNING: This piece was first posted by Watch List News and is the sole property of of Watch List News. If you are reading this piece on another website, it was stolen and reposted in violation of United States & international trademark and copyright law. The legal version of this piece can be accessed at https://www.watchlistnews.com/akcea-therapeutics-akca-downgraded-by-bidaskclub/1791225.html.

Akcea Therapeutics Company Profile

Akcea Therapeutics, Inc is a biopharmaceutical company. The Company is focused on developing and commercializing drugs to treat patients with serious cardiometabolic diseases caused by lipid disorders. The Company’s drugs, volanesorsen, AKCEA-APO(a)-LRx, AKCEA-ANGPTL3-LRx and AKCEA-APOCIII-LRx, are all based on antisense technology developed by Ionis Pharmaceuticals, Inc (Ionis).

Receive News & Ratings for Akcea Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Akcea Therapeutics and related companies with Analyst Ratings Network's FREE daily email newsletter.